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The effect of levodopa on bilateral coordination and gait
asymmetry in Parkinson’s disease using inertial sensor
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This study aimed to evaluate the effect of levodopa on the phase coordination index (PCI) and gait asymmetry (GA) of patients with
Parkinson’s disease (PD) and to investigate correlations between the severity of motor symptoms and gait parameters measured
using an inertial sensor. Twenty-six patients with mild-to-moderate-stage PD who were taking levodopa participated in this study.
The Unified Parkinson’s Disease Rating Scale part III (UPDRS III) was used to assess the severity of motor impairment. The Postural
Instability and Gait Difficulty (PIGD) subscore was calculated from UPDRS III. Patients were assessed while walking a 20-m corridor in
both “OFF” and “ON” levodopa medication states, and gait analysis was performed using inertial sensors. We investigated the
changes in gait parameters after taking levodopa and the correlations between UPDRS III, PIGD, and gait parameters. There was a
significant improvement in PCI after taking levodopa. No significant effect of levodopa on GA was found. In “OFF” state, PCI and GA
were not correlated with UPDRS III and PIGD. However, in “ON” state, PCI was the only gait parameter correlating with UPDRS III,
and it was also highly correlated with PIGD compared to other gait parameters. Significant improvement in bilateral-phase
coordination was identified in patients with PD after taking levodopa, without significant change in gait symmetricity. Considering
the high correlation with UDPRS III and PIGD in “ON” states, PCI may be a useful and quantitative parameter to measure the severity
of motor symptoms in PD patients who are on medication.
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INTRODUCTION
Variable patterns of gait disturbance can be found in patients with
PD, including the problems of gait initiation, freezing of gait,
reduced balance and postural control, reduced step lengths,
increased step times, and slow walking speed1–3. Since assessing
gait clinically just based on a few items on the Unified Parkinson’s
Disease Rating Scale (UPDRS) may not be objective and
quantitative3, gait analysis could potentially be a promising tool
for obtaining objective and quantitative information on the
walking behavior of PD patients. Several gait parameters, such
as step length, gait speed, and variability, have been used to
evaluate the degree of motor impairment and to investigate the
effect of levodopa on those parameters in previous studies1,4–8.
Gait asymmetry (GA) can be used to assess the contribution of
cognitive function to gait symmetricity9, and it is a spatiotemporal
parameter calculated by step length, swing time, or stance time10.
The phase coordination index (PCI), which reflects bilateral
coordination of gait, is a temporal measure that quantifies the
accuracy of antiphase coordination and the consistency of
left–right stepping11. Both GA and PCI values are higher in PD
patients as compared to elderly subjects or healthy adults, since
the impaired inputs from basal ganglia to neuronal circuits are
manifested in the poor bilateral coordination of gait in patients
with PD9. In addition, GA and PCI are distinctive from each other.
While GA (i.e., left–right swing times) may reflect the degrees of
similarity in the motor function, left–right step-phase coordination
(PCI) may represent the degrees to which the rhythmic process of
stepping with one leg is coordinated with the rhythmic process of
stepping with the other one9. Those parameters have been used
to assess the symmetricity and rhythmicity of gait in PD patients,
and seem to be closely related to motor impairments9. However,
no study has investigated the correlation between the severity of
motor impairment and those parameters.
In addition, inertial measurement unit (IMU) systems have been
proposed as an alternative tool for gait analysis12–14, as they are
relatively inexpensive, simple, wearable, and require a relatively
smaller amount of laboratory space than more conventional
systems, such as optical motion capture systems15,16. Several
validity studies have compared IMU systems to optical motion
capture systems15,17, confirming that IMU systems can be easy and
reliable means to measure gait events in patients with PD. Curtze
et al. investigated the responsiveness to levodopa on variable gait
parameters using six inertial sensors in 104 subjects with PD, and
found improvements in stride velocity, stride length, and range of
motion18. However, the effects of levodopa on GA or PCI still
remain unclear.
Therefore, the purpose of the present study was to evaluate the
effects of levodopa on GA and PCI in PD patients, and to
investigate the correlation between the severity of the motor
symptoms and those gait variables as measured by IMU systems.
We hypothesized that GA and PCI might show higher responsive-
ness on levodopa than other gait parameters, and could be used
as a quantitative indicator to assess the severity of motor
symptoms in patients with PD.
RESULTS
Change of clinical and gait parameters after the levodopa
challenge test
The results of the levodopa challenge test are presented in Table 1.
In all patients, the average UPDRS III (P < 0.001) and PIGD (P=
0.003) significantly improved after taking levodopa medication.
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The average PCI (P= 0.008) significantly decreased after taking
medication, and the post hoc power was 0.87 for PCI. There was no
significant difference in GA (P= 0.123). In the “ON” state, gait
speed (P= 0.039), step length (P= 0.031), and the cadence (P=
0.035) were significantly higher than those in the “OFF” state. The
SRM analysis revealed that levodopa induced the largest improve-
ment in PCI (SRM=−0.64) among all variables. The UPDRS III
(SRM=−0.52) showed moderate response to levodopa. The other
gait variables (SRM= 0.03–0.5) showed small responsiveness.
Correlation between clinical and gait parameters
The Pearson correlation analysis with Bonferroni correction
between UPDRS III, PIGD, and other variables is presented in
Table 2. In the “OFF” state, there was no variable correlating with
UPDRS III. Interestingly, in the “ON” state, PCI (R= 0.641, P= 0.001)
was the only gait parameter that correlated with UPDRS III. PIGD
was negatively correlated with gait speed (R=−0.642, P < 0.001)
and step length (R=−0.621, P < 0.001) in the “OFF” state. In the
“ON” state, PCI (R= 0.647, P < 0.001) was the only gait parameter
that correlated with PIGD.
Partial correlation analysis controlling the relevant covariate
with Bonferroni correction is presented in Table 3. In the “OFF”
state, UPDRS III was found to be significantly correlated with gait
speed (R=−0.674, P= 0.001) and step length (R=−0.704, P <
0.001). GA and PCI were not related with UPDRS III in the “OFF”
state. However, in the “ON” state, PCI (R= 0.657, P= 0.002) was
the only gait parameter that correlated with UPDRS III. PIGD was
also significantly correlated with PCI (R= 0.653, P= 0.002) in the
“ON” state. Gait speed (R=−0.604, P= 0.005) was related with
PIGD showing near-marginal significance in the “ON” state.
DISCUSSION
In this study, we found that PCI markedly improved after levodopa
medication and that it was correlated with UPDRS III and PIGD in
the “ON” state. Among gait parameters, PCI was the only gait
parameter linked to UPDRS III and PIGD in the “ON” state. Previous
studies have shown that anti-PD medications can change the gait
patterns of patients during walking tasks;4,5,19 however, these
studies investigated only spatiotemporal parameters, such as gait
speed and step length. Bryant et al.4 reported that PD patients in
the “ON” state had significantly higher gait speeds, stride lengths,
and double-support times than those in the “OFF” state. Lubik
et al.19 reported that gait velocities and step lengths were higher
in PD patients treated with levodopa than before treatment.
Although the present study identified consistent results for
spatiotemporal gait parameters after levodopa treatment, the
primary aim of our study involved identifying the changes in PCI
and GA after medication. To our best knowledge, this is the first
study to investigate the effects of anti-parkinsonian medications
on PCI and GA measured by an IMU system.
We selected the shoe-type IMU system for the measurement of
PCI and GA, as IMU sensors attached to both lower limbs may
increase the detection accuracy of gait sequences, such as the
heel-strike and toe-off sequences. In addition, these sensors are
relatively inexpensive, simple to use, and are wearable for patients
with PD16. The shoe-type IMU system used in our study used
sensors mounted in the outsoles of shoes beneath the back of
each foot, maintaining the stability of sensor positions without
hindering movement. In the validity analysis for shoe-type IMU
system used in our study and motion capture system, the
resultant linear accelerations for 17 patients with PD indicated
excellent agreement (ICC: 0.990–1.000) for spatiotemporal para-
meters, including cadence, step time, and step length20.
We found that PD patients showed the largest improvement in
PCI after taking levodopa medications. In the “ON” state, PCI
showed a high correlation with both UPDRS III and PIGD. Impaired
rhythmicity of gait in PD may reflect reduced automaticity and
damaged locomotor synergies, and the basal ganglia was thought
to play an important role in initiating and regulating motor
programs involved in gait21. It was found that levodopa therapy
could reduce variability in PD, demonstrating the role dopami-
nergic pathways play in the impaired gait rhythmicity in PD using
the dopa challenge test22,23. We assumed that levodopa improves
PCI by reducing the variability of gait. In addition, although the
step length and gait speed had a significant correlation with
UPDRS III and PIGD in the “OFF” states, it is unnecessary and
dangerous for patients with PD to undergo gait analysis in the
“OFF” state in the clinical situation. Our results indicate that PCI
can be a more useful indicator of the severity of motor
impairments in PD patients during levodopa medications
compared to other gait parameters.
There were no significant changes in GA after taking anti-PD
medications; furthermore, GA showed no correlation with the
UPDRS III and PIGD in both “OFF” and “ON” states. Yogev et al.9
reported that no correlations were found between GA and the
asymmetry of classic PD motor symptoms. It has been reported
that GA reflects the degree of similarity in motor function for leg
propulsion on both sides of the body, while PCI represents the
degree to which the rhythmic process of stepping with one leg is
coordinated with the rhythmic process of stepping with the other
leg24. Similar to previous studies, our results indicate that GA
cannot be used to assess medication response nor the severity of
motor symptoms in PD patients.
Table 1. Comparison of gait characteristics between “Off” and “On”
states.
Off state On state P value SRM
UPDRS III score 27.7 ± 12.0 22.1 ± 11.1 <0.001 −0.52
PIGD 5.35 ± 2.19 4.62 ± 1.92 0.003 −0.33
PCI (%) 4.39 ± 1.64 3.33 ± 1.84 0.008 −0.64
φ 179.0 ± 6.6 177.8 ± 2.5 0.409
φ_CV 2.4 ± 2.8 1.9 ± 0.9 0.380
φ_ABS 5.4 ± 4.9 3.7 ± 1.6 0.069
GA 3.21 ± 2.05 2.53 ± 1.49 0.123 −0.33
Numbers of steps 49.6 ± 16.8 42.4 ± 13.3 0.007 −0.43
Pace
Gait speed (m/s) 1.06 ± 0.25 1.12 ± 0.25 0.039 0.31
Step length (m) 0.55 ± 0.12 0.58 ± 0.11 0.031 0.24
Cadence (step/min) 110.6 ± 10.1 115.6 ± 13.4 0.035 0.49
Rhythm
Step time (ms) 515 ± 36 511 ± 34 0.681 −0.11
Step swing time (ms) 409 ± 30 408 ± 35 0.925 −0.03












0.021 ± 0.030 0.016 ± 0.015 0.509 −0.15
SRM standardized response mean, UPDRS Unified Parkinson’s Disease
Rating Scale, PIGD postural instability and gait difficulty, PCI phase
coordination index, GA gait asymmetry.
Values are expressed as mean ± standard deviation.
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We observed that step length and gait speed had a moderate
correlation with UPDRS III and PIGD in the “OFF” state. However, in
the “ON” state, gait speed was associated with only PIGD showing
only borderline significance. The UPDRS III is based on the severity
of overall dysfunction of motor symptoms in PD patients25, and
PIGD used in our study was calculated from UPDRS III (arising from
a chair, standing posture, gait, and postural stability/pull test)18.
We assume that PIGD may be more closely correlated with gait
parameters than UPDRS III. A further study investigating the
relationship between gait parameters and clinical scores closely
related to gait is needed.
Gait analysis has received widespread attention as part of an
objective and quantitative assessment for examining PD patients.
The advances in wearable technology have made it possible for
clinics to easily assess gait parameters, such as PCI. Although the
foot-positioned IMU systems used in our study are comfortable
devices for PD patients, they are still only available in tertiary
hospitals equipped with motion analysis equipment. Most devices
developed for community-based monitoring are based on the
performance of tasks that mimic the neurological examination
based on UPDRS26,27. In the future, a new generation of mobile
devices combined with IMU systems could improve health care by
providing gait assessments outside the hospital.
This study had several limitations. First, since our findings were
obtained from the acute levodopa challenge test, caution is
needed when applying them directly to the clinical situations. But,
the levodopa challenge test is known to be an excellent method
for patients to obtain the extent to which parkinsonian motor
symptoms respond to levodopa by evaluating the UPDRS III and
gait28. Second, the “ON” and “OFF” medication conditions were
not randomized. Although randomizing these conditions would
have enabled avoidance of a practice effect, we preferred to ask
patients to do the required 12-h pharmacological washout during
nighttime hours and perform the evaluation in the morning for
logistical and ethical reasons. Third, we only included patients
who could independently walk a relatively long distance of 20 m
several times. Compared to previous studies, we found lower LED
and UPDRS III and relatively higher cadence and gait speed in the
included patients. Therefore, our results may only be applied to
patients with mild PD. Further research is needed to apply our
results in moderate-to-severe PD patients. Fourth, we used the
original UPDRS in this study, as many previous studies investigat-
ing the gait in PD used the original UPDRS4,5,7,8,18,29–31. The MDS-
UPDRS is known as the new version of the UPDRS, and is designed
to be more comprehensive than the original UPDRS32. However,
the correlation between MDS-UPDRS and UPDRS was excellent for
both total score (R= 0.96) and part III subscore (R= 0.96) in a
previous study32.
In conclusion, we identified a significant improvement in
bilateral-phase coordination after levodopa administration in
patients with PD; however, there were no significant changes
in GA. In addition, PCI was a gait parameter highly associated with
the severity of motor impairments in the “ON” state, indicating
that this index may be a useful and quantitative parameter for
measuring the severity of motor symptoms in PD patients who are
on medication.
Table 2. Results of correlation analysis between UPDRS III, PIGD, and all parameters.
Variables UPDRS III PIGD
Off state On state Off state On state
R P value R P value R P value R P value
Age −0.140 0.494 0.094 0.649 −0.072 0.727 0.183 0.372
Height −0.153 0.456 −0.011 0.959 −0.155 0.449 0.034 0.869
BMI −0.294 0.145 −0.237 0.244 0.057 0.781 −0.001 0.995
H&Y stage 0.399 0.043 0.526 0.010 0.273 0.177 0.441 0.024
Treatment duration 0.029 0.887 0.012 0.955 0.161 0.433 0.114 0.581
LED 0.375 0.059 0.201 0.326 0.419 0.033 0.272 0.179
Gait parameters
PCI 0.454 0.023 0.641 0.001* 0.361 0.076 0.647 <0.001*
GA 0.479 0.016 0.424 0.035 0.439 0.029 0.381 0.060
Pace
Gait speed −0.500 0.009 −0.375 0.059 −0.642 <0.001* −0.493 0.011
Step length −0.492 0.011 −0.356 0.074 −0.621 <0.001* −0.452 0.020
Cadence 0.030 0.884 0.266 0.189 0.074 0.721 0.086 0.675
Rhythm
Step time 0.118 0.567 0.141 0.491 0.199 0.330 0.268 0.186
Step swing time 0.031 0.881 0.047 0.822 0.246 0.225 0.212 0.298
Step stance time 0.133 0.517 0.189 0.355 0.124 0.547 0.254 0.211
Asymmetry
Step-time asymmetry −0.135 0.510 −0.097 0.646 −0.290 0.151 0.138 0.511
Variability
Step-length variability 0.335 0.109 0.162 0.449 −0.012 0.956 0.165 0.440
Postural control
Step-length asymmetry 0.301 0.135 −0.180 0.380 0.238 0.241 −0.194 0.342
UPDRS Unified Parkinson’s Disease Rating Scale, PIGD postural instability and gait difficulty, BMI body mass index, H & Y Hoehn and Yahr, LED levodopa
equivalent dose, PCI phase coordination index, GA gait asymmetry.
*Significantly correlated after Bonferroni correction at P value <0.0029 (0.05/17).
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METHODS
Participant
Patients were considered eligible for inclusion in this acute levodopa
challenge study if they were diagnosed with idiopathic PD based on the
United Kingdom Brain Bank criteria25,33, had mild-to-moderate-stage PD
(H&Y stage: 2–3), were currently taking levodopa medications, were able to
walk unassisted, and had a Mini-Mental Status Examination (MMSE) of >24/
3034. Patients were excluded if they presented with any musculoskeletal
and neurological disorder, other than idiopathic PD, that could affect gait.
After consideration of the eligibility criteria, 26 patients with PD were
enrolled in this study. Baseline demographic characteristics of study
participants are presented in Table 4. At baseline, age, sex, height, weight,
H&Y stage, MMSE, Montreal Cognitive Assessment (MoCA), UPDRS total
score, disease duration, duration of levodopa treatment, and levodopa
equivalence dose (LED) were assessed for each eligible patient. Two
cognitive screening tests (MMSE and MoCA) were conducted, since the
cognitive function can affect gait. MMSE is the primary screening tool and
the most commonly used instrument in PD35,36. MoCA is considered a
better measurement of cognitive status in PD, as it lacks both ceiling and
floor effect37.
This study was approved by the Institutional Review Board of our
institution (IRB No. 3-2018-0095). Each participant provided his or her
written informed consent before participating in this study.
Patient assessment
Gait assessment was first performed in an “OFF” levodopa state and then
in an “ON” levodopa state, for each participant on the same day. For “OFF”
medication testing, participants were evaluated in the morning after
abstaining from levodopa medications for a minimum of 12 h prior to the
trial. After “OFF” testing, participants took their usual levodopa medica-
tions. The peak of levodopa effect was subjectively determined by patients
as the best “ON” state and was thus variable; however, most studies set this
assessment period at 1 h18,29, knowing that the half-life of levodopa is
around 1.5 h38. When both the patient and the evaluator agreed with the
best “ON” state for gait analysis, the patient then took walking tests for the
“ON” medication testing. The mean waiting time after the medication was
approximately 1–1.5 h. Each patient underwent two trials of walking tests
in each state, and the average values from the two trials in each state were
used to increase the reliability of data. After each trial, patients rested on a
chair for at least 2 min to avoid the effects of fatigue.
For the walking tests, participants were asked to walk forward along a
20-m-long and 2-m-wide corridor at their normal pace. A recent study
reported that more than 23 strides were required to obtain a reliable,
characteristic PCI value39. This means that calculating PCI using gait data
obtained by ground walking on a short distance may be unreliable.
Therefore, in our study, gait analysis was performed on 20-m-long corridor
to collect gait data on more than 23 strides. The gait protocol was
performed with an IMU sensor-based gait analysis system (DynaStab™,
JEIOS, South Korea) consisting of a shoe-type data logger (Smart Balance1
SB-1, JEIOS, South Korea) and a data acquisition system (DynaStab-
Spotfire1, Tibco Spotfire 7.10) (Fig. 1). The shoe-type data logger included
an IMU sensor (IMU-3000™, InvenSense, USA) that measured triaxial
acceleration (up to ± 6 g) and triaxial angular velocity (up to ± 500° s− 1)
along three orthogonal axes12,16. The IMU sensors were installed in both
shoe outsoles, and the data were transmitted wirelessly to a data
Table 3. Results of partial correlation analysis between UPDRS III, PIGD, and gait parameters.
Gait parameters UPDRS III PIGD
Off state On state Off state On state
R P value R P value R P value R P value
PCI 0.398 0.091 0.657 0.002* 0.510 0.026 0.653 0.002*
GA 0.416 0.077 0.439 0.060 0.382 0.106 0.420 0.073
Pace
Gait speed −0.674 0.001* −0.506 0.023 −0.697 <0.001* −0.604 0.005
Step length −0.704 <0.001* −0.506 0.023 −0.719 <0.001* −0.577 0.008
Cadence 0.108 0.650 0.379 0.100 0.137 0.563 0.147 0.536
Rhythm
Step time 0.039 0.869 0.055 0.818 0.308 0.186 0.305 0.191
Step swing time 0.014 0.954 0.036 0.882 0.332 0.153 0.309 0.186
Step stance time 0.042 0.860 0.057 0.810 0.200 0.398 0.219 0.353
Asymmetry
Step-time asymmetry −0.282 0.229 −0.011 0.964 −0.300 0.199 0.202 0.407
Variability
Step-length variability 0.164 0.516 0.216 0.389 −0.017 0.946 0.292 0.240
Postural control
Step-length asymmetry 0.104 0.661 −0.152 0.523 0.098 0.681 −0.238 0.313
UPDRS Unified Parkinson’s Disease Rating Scale, PIGD postural instability and gait difficulty, PCI phase coordination index, GA gait asymmetry.
*Significantly correlated after Bonferroni correction at P value <0.0045 (0.05/11).
Table 4. Demographic data of the included patients.
Variables Total (26 patients)
Age (years) 71.8 ± 6.7
Height (m) 1.6 ± 0.1
Weight (kg) 64.2 ± 8.5
Body mass index (kg/m²) 24.1 ± 3.1
Sex (M:F) 18:8
H&Y stage 2.2 ± 0.3
MMSE 26.3 ± 3.3
MoCA 23.1 ± 5.0
UPDRS total 35.7 ± 15.2
Disease duration (years) 4.9 ± 2.9
Duration of levodopa treatment (years) 3.7 ± 2.8
Levodopa equivalent dose (mg/day) 450.3 ± 213.7
H&Y Hoehn and Yahr, MMSE Mini-Mental State Examination, MoCAMontreal
Cognitive Assessment, UPDRS Unified Parkinson’s Disease Rating Scale.
Values are expressed as mean ± standard deviation.
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acquisition system via Bluetooth®. Shoe sizes were adapted to each
participant, with available sizes ranging from 225mm to 280mm. The local
coordinate system for the IMU sensors included the anteroposterior,
mediolateral, and vertical directions.
The UPDRS III was used to assess the degree of motor impairment in all
participants. Patients were assessed for their UPDRS III in both “OFF” and
“ON” medication states by a neurologist who was blinded to the study
hypothesis. The Postural Instability and Gait Difficulty (PIGD) four-item
subscore was calculated from the UPDRS III (arising from a chair, standing
posture, gait, and postural stability/pull test)18.
Gait analysis
Spatiotemporal parameters were measured using the shoe-type IMU
sensor-based gait analysis system. Data on gait speed, cadence, step time,
step stance time, step swing time, and step length on each side were
collected. The rationale for the selection of gait parameters into the factor
analysis was informed by a comprehensive model of gait developed for
older adults40 and validated in PD41. The model comprises five
independent domains: pace, variability, rhythm, asymmetry, and postural
control42.
The PCI quantifies the bilateral coordination of left–right stepping,
according to the equations proposed by Plotnik et al.9 PCI incorporates
assessments of the accuracy and consistency of phase generation, with the
step time being used to determine the phase (φ). Normalizing the step
time with respect to the stride time defines the phase of the ith stride (φi)9.
We first calculated the mean values of swing times for both legs. We then
used the leg with the higher average swing time as a reference for the gait
cycles, and calculated the phase values for the other leg. Therefore, φi was
defined as φi= 360° × (tSi− tLi)/(tL(i+ 1)−tLi), where tLi and tSi denoted
the time of the ith heel strike of the legs with the longer and shorter swing
times, respectively9. We considered the phase (φ) as the fluctuation about
an ideal line of 180° for each step. φ_ABS was the phase-generation
accuracy and was calculated as the mean value of a series of absolute
differences between the phase at each stride and 180°. Therefore, φ_ABS
was defined as φ_ABS= | φi− 180°|9. φ_CV was measured as the level of
consistency in phase generation across all of a participant’s strides. Finally,
PCI was calculated as the sum of the two percentile values: PCI= φ_CV+
Pφ_ABS, where Pφ_ABS equaled 100 × (φ_ABS/180)9. Lower PCI values
indicated a more consistent and accurate phase generation, which is
associated with different health conditions, and higher PCI values
indicated a more impaired bilateral gait coordination24. The range of the
mean PCI in healthy young adults known in previous studies was
2.4–3.211,24,43,44.
GA was assessed by comparing the swing times performed by one leg
with respect to the swing times performed by the other, according to the
following formula: GA= 100 × | ln(SSWT/LSWT) | , where SSWT and LSWT
were the mean values of the swing times for the legs with the shortest and
longest mean swing times, respectively9,10. We calculated the GA using this
method, as it has commonly been used in previous studies45,46. Using this
definition, a value of 0.0 reflected perfect symmetry, and higher values
reflected greater degrees of asymmetry9.
Step-time asymmetry and step-length asymmetry were calculated as the
absolute differences between the mean of the left and the right steps.
Step-length variability was calculated using the standard deviation (SD),
rather than coefficient of variation (defined as mean/SD × 100), because it
provides clarity for interpretation47.
Statistical analysis
At study commencement, we performed an a priori power analysis for the
change of UPDRS III, since there was no previous study investigating the
change of PCI. A generic inverse-variance method with the fixed-effects
model was used to compute pooled estimates of the effect sizes. This
analysis showed that a minimum sample size of 26 patients was required
to achieve a statistical significance of 0.05 with an 80% power at an overall
effect size of 0.58 for the change of UPDRS III, based on five recent studies
investigating the change of gait parameters on levodopa challenge
test5,7,18,30,48. Sample-size calculation was performed using R (version 4.0.3,
R Foundation for Statistical Computing, Vienna, Austria). The post hoc
power analysis for the change of PCI was performed using a G Power test
(Version 3.1.9.2).
All variables were tested for normality using the Shapiro–Wilk test, and
none was found to violate the normal distribution assumption. Descriptive
statistical analysis using means and standard deviations were used to
describe the characteristics of each variable. Paired-sample t tests were
used to identify significant differences between variables in “OFF” and
“ON” states. Responsiveness of the clinical and gait variables to levodopa is
expressed as the standardized response mean (SRM). SRM was calculated
as the observed mean change divided by the standard deviation of the
observed change. SRM is the preferred value to compare paired data
measurements at different time points for the same patient. SRM values of
0.8, 0.5, and 0.2 were considered to be large, moderate, and small,
respectively49.
Pearson correlation analysis was conducted to examine the relationships
between UPDRS III, PIGD, and clinical gait parameters. This analysis
described the direction and strength of the relationship between two
continuous variables in our study, where the direction could be negative or
positive. The correlation between UPDRS III, PIGD, and gait parameters was
investigated through partial Pearson’s correlations adjusted for age, height,
BMI, H&Y stage, duration of levodopa treatment, and LED. Bonferroni
correction was applied for multiple comparisons in each analysis. All
statistical analyses were performed using SPSS (version 25.0, SPSS. Inc.,
Chicago, IL). P values <0.05 were considered to be statistically significant.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
Fig. 1 Inertial sensors are mounted on the shoes. Shoe-type data logger can record gait data continuously during walking. The collected
gait data is transferred to the data processing device via Bluetooth wirelessly.
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The data that support the findings of this study are available from the corresponding
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CODE AVAILABILITY
Sample-size calculation was performed using R (version 4.0.3, R Foundation for
Statistical Computing, Vienna, Austria). The post hoc power analysis for the change of
PCI was performed using a G Power test (Version 3.1.9.2). Statistical analyses were
performed using SPSS (version 25.0, SPSS. Inc., Chicago, IL).
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